Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Merck wins 1st FDA approval for Keytruda
Merck wins first FDA approval for Keytruda as a treatment for mesothelioma
Merck & Co. Inc. said Wednesday the U.S. Food and Drug Administration has approved its blockbuster cancer drug Keytruda as a treatment for malignant plural mesothelioma, a rare cancer associated with asbestos.
Merck's Keytruda Obtains its First FDA Approval for Mesothelioma
Merck & Co., Inc. MRK announced that the FDA had approved its blockbuster anti-PD-1 therapy, Keytruda (pembrolizumab), for a new indication. The regulatory body has now approved Keytruda in combination with pemetrexed and platinum chemotherapy for the first-line treatment of adult patients with unresectable advanced or metastatic malignant pleural mesothelioma (MPM).
Keytruda Plus Chemotherapy Approved for Malignant Pleural Mesothelioma
The FDA has approved Keytruda in combination with pemetrexed and platinum chemotherapy, as first-line Tx of unresectable advanced or metastatic malignant pleural mesothelioma.
Merck Gets First FDA Approval of Keytruda in Malignant Pleural Mesothelioma
Merck & Co. has won its first U.S. approval for use of its blockbuster cancer drug Keytruda in patients with malignant pleural mesothelioma, a rare cancer that grows in the membrane that lines the walls of the chest and lungs.
FDA Approves Keytruda Plus Chemo for Pleural Mesothelioma Subset
Keytruda plus chemo has been approved for unresectable advanced or metastatic malignant pleural mesothelioma based on findings from the KEYNOTE-483 trial.
Pembrolizumab Approved With Chemotherapy for Malignant Pleural Mesothelioma
Pembrolizumab (Keytruda, Merck) has picked up another indication — this time for the first-line treatment of unresectable advanced or metastatic malignant pleural mesothelioma (MPM) in combination with pemetrexed and platinum chemotherapy.
Merck's Keytruda Secures First FDA-Approval For Rare Form Aggressive Cancer
Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy for the first-line treatment of adult patients with unresectable advanced or metastatic malignant pleural mesothelioma (MPM).
Merck: KEYTRUDA Plus Chemotherapy Gets FDA Approval For Malignant Pleural Mesothelioma In Adults
Drug major Merck & Co., Inc. (MRK) announced Wednesday that the U.S. Food and Drug Administration has approved its anti-PD-1 therapy
GlobalData on MSN
1d
MHLW approves MSD’s KEYTRUDA for lung and urothelial cancers
The Japanese MHLW has granted approval for MSD’s KEYTRUDA (pembrolizumab) for lung and urothelial cancer indications.
2d
Merck fails in late-stage trial for Keytruda combo in colon cancer
Merck (MRK) stock is in focus as a Phase 3 trial for its cancer drug Keytruda in colorectal cancer patients did not meet ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Trending now
High-end brothel plea
Helene: How to help
'Harry Potter' star dies
ICE: Convicts roaming free
Troops to leave some bases
Stadiums to serve as shelters
Promotes watch collection
Targeted Black residents?
World's oldest cheese found
Diocese reaches settlement
Killer gets life sentence
Deposition in AI suit
KY sues Express Scripts
Fed inflation gauge cools
Ending password-sharing
More executives leave
ISR targets Hezbollah HQ
US charges three Iranians
NIH finds misconduct
On Secret Service failures
Urgent safety alert for 737s
Pleads not guilty
Meta hit with privacy fine
Fake Biden robocalls fine
50/50 ball ownership suit
Boxes to distribute Narcan
Producing doc on Diddy
NC board removes 747K
WI duplicate ballot flap
Feedback